We are live on ! Find out more
NXTC icon

NextCure

43 hedge funds and large institutions have $15.3M invested in NextCure in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

68% more capital inflows, than outflows

Capital inflows: $1.3M | Capital outflows: $773K

10% more funds holding

Funds holding: 39 → 43 (+4)

1.5% more ownership

Funds ownership: 46.32% → 47.82% (+1.5%)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
6
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NXTC Hedge Fund Activity: Q4 2023 in Review

43 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q4 2023, worth a combined $15.3M — down 8.2% from $16.6M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NXTC positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 9 trimmed.

The largest buyer was Acuitas Investments, adding an estimated $104K. The largest seller was Millennium Management, cutting an estimated $341K.

  • 43 institutional investors held NextCure (NXTC) as of Q4 2023, up from 39 in Q3 2023.
  • Funds reported $15.3M of NextCure stock for Q4 2023, down 8.2% quarter-over-quarter.
  • 9 funds opened new NextCure positions in Q4 2023 and 5 closed out, a net change of +4 holders.
  • The largest NextCure buyer in Q4 2023 was Acuitas Investments, an estimated $104K added.
  • The largest NextCure seller in Q4 2023 was Millennium Management, an estimated $341K sold.

Based on aggregated 13F filings for Q4 2023.